|Bid||2.4000 x 2200|
|Ask||2.5000 x 1800|
|Day's Range||2.4200 - 2.4500|
|52 Week Range||2.0000 - 5.0000|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 25, 2018 - Jul 30, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||30.00|
Pernix Therapeutics Holdings, Inc. (PTX), a specialty pharmaceutical company, today announced that Nalpropion Pharmaceuticals, Inc. (“Nalpropion”), the special purpose vehicle (“SPV”) created by Pernix and an investor group (collectively with Pernix, the “Investors”), has been informed by Orexigen Therapeutics, Inc. (“Orexigen”) that no other bids for Orexigen’s assets were received by the court-approved bid deadline. Accordingly, Nalpropion anticipates being declared the highest and best bidder for the assets and closing on the transaction by July 13, 2018, subject to satisfaction of the closing conditions, including court approval. In April 2018, Nalpropion entered into a “stalking horse” asset purchase agreement to acquire certain assets of Orexigen, including worldwide rights to Contrave® (naltrexone HCl / bupropion HCl), a prescription-only weight loss medication, for $75 million in cash.
MORRISTOWN, N.J., May 10, 2018-- Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company, announced today its financial results for the three months ended March 31, 2018.. First Quarter ...
John Sedor took the helm as Pernix Therapeutics Holdings Inc’s (NASDAQ:PTX) CEO and grew market cap to US$28.02M recently. Understanding how CEOs are incentivised to run and grow their companyRead More...
MORRISTOWN, N.J., May 01, 2018-- Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company, announced today that the Company will report financial results for the first quarter ended March ...
MORRISTOWN, N.J, April 23, 2018-- Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company, today announced that it has agreed to participate in an investor group that has entered into a“ ...
If you are looking to invest in Pernix Therapeutics Holdings Inc’s (NASDAQ:PTX), or currently own the stock, then you need to understand its beta in order to understand how itRead More...
Stock Monitor: Pernix Therapeutics Holdings Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 6, 2018 / Active-Investors.com has just released a free research report on Amarin Corp. PLC (NASDAQ: ...
In this article, I’m going to take a look at Pernix Therapeutics Holdings Inc’s (NASDAQ:PTX) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subjectRead More...
|Downgrade||Brean Capital: to Hold||8/12/2016|
|Downgrade||Oppenheimer: to Perform||3/17/2016|
|Downgrade||Needham: to Hold||3/11/2016|
|Initiated||Brean Capital: to Buy||6/29/2015|
|Initiated||PiperJaffray: to Overweight||4/22/2015|
|Initiated||Oppenheimer: to Outperform||3/25/2015|
Industry: Drug Manufacturers - Specialty & Generic
Full Time Employees: 171
Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription drugs primarily for the United States market. It targets underserved therapeutic areas, such as central nervous system (CNS), including pain, neurology, and psychiatry. The company's products comprise Zohydro ER with BeadTek, an opioid agonist indicated for the management of pain; Silenor, a non-narcotic, non-scheduled, and non-addictive prescription sleep aid for the treatment of insomnia characterized by difficulty with sleep maintenance; and Treximet, a fixed dose combination product indicated for the treatment of acute migraine. Pernix Therapeutics Holdings, Inc. markets and sells its non-core products, including generics through its wholly owned subsidiaries; and markets its non-promoted products through distributors and trade partners. It serves drug wholesalers, specialty pharmacies, retail drug stores, mass merchandisers, and grocery store pharmacies. Pernix Therapeutics Holdings, Inc. was founded in 1996 and is headquartered in Morristown, New Jersey.